Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

Table 1 Patient characteristics

Characteristics	Data (n = 6)
Gender
Male	3 (50)
Female	3 (50)
Age (yr)	70 (47-81)
Tumor stage IV1	6 (100)
Localization1
Right	2 (33.3)
Sigmoid	2 (33.3)
Rectal	1 (16.7)
Mucinous appendix	1 (16.7)
KRAS status1
Mutated	6 (100)
Normal	0 (0)

¹Evaluated before chemotherapy. Data are n (%).

Table 2 Normalized CXCL5 gene expression levels and progression-free survival after bevacizumab-containing treatment onset in the six cases reported in this study

Case number	1	2	3	4	5	6
PFS after BVZ-containing treatment onset (mo)	18	12	12	3	6	3
Overall PFS after BVZ-containing treatment onset (mo)	12 (12-18)			3 (3-6)
Normalized CXCL5 gene expression	10.700	3.655	0.002	23.430	20.390	32.900
Overall normalized CXCL5 gene expression	3.655 (0.002-10.700)			23.430 (20.390-32.900)

Overall data are median (range). BVZ: Bevacizumab; PFS: Progression-free survival.